Efficacy and safety of CAR T-cell therapy in patients with primary or secondary CNS lymphoma: A study on behalf of the EBMT and the GoCART coalition.

Hemasphere · 2025 · PMC12093105 · PMID 40400509

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

showed a trendno p-value reported

Patients previously irradiated showed a trend for better PFS and OS (2‐year PFS and OS 47% [95% CI 27–83] and 63% [95% CI 43–91]) compared to patients without prior CNS radiation (25% [95% CI 17–39] and 34% [95% CI 24–47] ( p = 0.18).

also in 53,322 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.